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Characteristic features of Alzheimer’s disease are memory loss, plaques resulting from abnormal processing of amyloid precursor
protein (APP), and presence of neuroﬁbrillary tangles and dystrophic neurites containing hyperphosphorylated tau. Currently, it is
not known what links these abnormalities together. Cytoplasmic FMR1 interacting protein 2 (CYFIP2) has been suggested to
regulate mRNA translation at synapses and this may include local synthesis of APP and alpha-calcium/calmodulin-dependent
kinase II, a kinase that can phosphorylate tau. Further, CYFIP2 is part of the Wiskott-Aldrich syndrome protein-family verprolin-
homologous protein complex, which has been implicated in actin polymerization at synapses, a process thought to be required for
memory formation. Our previous studies on p25 dysregulation put forward the hypothesis that CYFIP2 expression is reduced in
Alzheimer’s disease and that this contributes to memory impairment, abnormal APP processing and tau hyperphosphorylation.
Here, we tested this hypothesis. First, in post-mortem tissue CYFIP2 expression was reduced by 50% in severe Alzheimer’s
hippocampus and superior temporal gyrus when normalized to expression of a neuronal or synaptic marker protein. Interestingly,
there was also a trend for decreased expression in mild Alzheimer’s disease hippocampus. Second, CYFIP2 expression was reduced
in old but not in young Tg2576 mice, a model of familial Alzheimer’s disease. Finally, we tested the direct impact of reduced
CYFIP2 expression in heterozygous null mutant mice. We found that in hippocampus this reduced expression causes an increase in
APP and b-site amyloid precursor protein cleaving enzyme 1 (BACE1) protein, but not mRNA expression, and elevates production
of amyloid-b42. Reduced CYFIP2 expression also increases alpha-calcium/calmodulin-dependent kinase II protein expression, and
this is associated with hyperphosphorylation of tau at serine-214. The reduced expression also impairs spine maturity without
affecting spine density in apical dendrites of CA1 pyramidal neurons. Furthermore, the reduced expression prevents retention of
spatial memory in the water maze. Taken together, our ﬁndings indicate that reduced CYFIP2 expression triggers a cascade of
change towards Alzheimer’s disease, including amyloid production, tau hyperphosphorylation and memory loss. We therefore
suggest that CYFIP2 could be a potential hub for targeting treatment of the disease.
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Introduction
Alzheimer’s disease is a neurodegenerative disease that
causes memory loss. The pathological hallmarks of
Alzheimer’s disease are the occurrence of amyloid plaques
and neuroﬁbrillary tangles, next to substantial neuronal
loss in forebrain (Braak and Braak, 1991; Hardy and
Selkoe, 2002). Amyloid plaques contain amyloid peptide
amyloid-b42 that has resulted from abnormal cleavage of
amyloid precursor protein (APP). Neuroﬁbrillary tangles
contain hyperphosphorylated forms of the microtubule
binding protein tau. Further, post-mortem brain analyses
have established that synapse loss precedes neuronal loss
in Alzheimer’s disease (Arendt, 2009). This synaptic degen-
eration correlates best with the memory impairment
(deKosky and Scheff, 1990; Terry et al., 1991; Coleman
et al., 2004). The initial cause of synaptic degeneration is
thought to be formation of soluble amyloid-b42 oligomers
(Marcello et al., 2008). Amyloid oligomers increase trans-
lation of APP mRNA at synapses of cultured neurons
(Westmark et al., 2011; Sadleir et al., 2014), suggesting
that increased APP expression contributes to amyloid tox-
icity (Westmark, 2013). Fragile X mental retardation pro-
tein (FMRP, encoded by FMR1) binds to APP mRNA and
prevents its translation (Westmark and Malter, 2007; Lee
et al., 2010). Interestingly, FMRP also prevents local trans-
lation of mRNA encoding a-isoform of calcium/calmodu-
lin-dependent kinase II (aCaMKII, encoded by CAMK2A)
(Darnell et al., 2011), a kinase implicated in tau hyperpho-
sphorylation and Alzheimer’s disease (Ghosh and Giese,
2015). FMRP binds to cytoplasmic FMRP-interacting pro-
teins 1 and 2 (CYFIP1 and CYFIP2) (Schenck et al., 2001).
Both of these proteins are expressed at synapses of hippo-
campal neurons (Pathania et al., 2014). CYFIP1 represses
cap-dependent translation of mRNA by interacting with the
initiation factor eIF4E (Napoli et al., 2008; Panja et al.,
2014; Genheden et al., 2015). CYFIP2 has an identical
eIF4E-binding motif as CYFIP1 (Napoli et al., 2008). In
addition to regulating translation of mRNA, CYFIP1 and
CYFIP2 are part of the Wiskott-Aldrich syndrome protein-
family verprolin-homologous protein (WAVE) complex
that regulates actin polymerization at synapses (Eden
et al., 2002; De Rubeis et al., 2013).
Our previous work showed that in the early stages of
Alzheimer’s disease expression of cyclin-dependent kinase
5 (Cdk5) activator p25 is reduced (Engmann et al.,
2011). This suggests that Cdk5-mediated phosphorylation
of tau may be decreased in Alzheimer’s disease, whereas
due to decreased inhibition by Cdk5 glycogen synthase
kinase 3b-mediated tau phosphorylation may be increased
(Giese, 2014). Further, we showed that p25 overexpression
upregulates CYFIP2 expression (Engmann et al., 2011).
Therefore, we hypothesized that in early Alzheimer’s dis-
ease CYFIP2 expression is reduced and this would contrib-
ute to synaptic degeneration. Here, we tested this
hypothesis by analysing CYFIP2 and CYFIP1 expression
in post-mortem Alzheimer’s disease brain tissue. We
found that CYFIP2 expression was reduced by 50%.
This effect was modelled in mice and we found that
reduced CYFIP2 expression leads to increased APP, b-site
APP cleaving enzyme 1 (BACE1), and aCaMKII protein
expression, abnormal amyloid-b42 production, tau hyper-
phosphorylation at serine-214, alterations in dendritic
spine morphology, and memory loss. Therefore, we suggest
that CYFIP2 could be one of the key targets for prevention
of Alzheimer’s disease.
Materials and methods
Post-mortem human brain samples
Human brain samples were obtained from the London
Neurodegenerative Diseases Brain Bank, Institute of Psychiatry,
Psychology and Neuroscience, King’s College London. They were
received in two sets, which were treated separately. The ﬁrst set
contained hippocampal tissue from control subjects, subjects with
mild Alzheimer’s disease (Braak stages I–II) and subjects with
severe Alzheimer’s disease (Braak stages V–VI) (n = 7 per
group), as well as superior temporal gyrus (STG) samples from
control and severe Alzheimer’s disease (n = 7 and n = 9, respect-
ively). The second set comprised hippocampus and STG samples
from control, mild and severe Alzheimer’s disease patients (n = 5
per group). The causes of death were not related to neurodegen-
erative disease in these control subjects (Supplementary Table 1).
All human tissue samples were handled according to the regula-
tions of King’s College London Neurodegenerative Diseases Brain
Bank and the Human Tissue Authority.
The frozen samples were lysed at 4C in RIPA lysis buffer
(Santa Cruz Biotechnology, Inc). The RIPA buffer contained
0.1% sodium dodecyl sulphate (SDS), 1% Nonidet P-40, 0.5%
sodium deoxycholate and 0.004% sodium azide in Tris-buf-
fered saline (TBS) (pH 7.5). Protease inhibitors cocktail,
sodium orthovanadate, and a-toluenesulphonyl ﬂuoride were
added to the buffer, diluted to 1:100. The SDS concentration
was increased by adding 0.25% SDS in the ﬁnal volume of
buffer. About 100mg of brain tissue was lysed in 300ml
buffer. Samples were homogenized using a dounce homogen-
izer (12 strokes, 700 rpm) and centrifuged at 3000 rpm for
10min. Supernatants were used for western blot analysis.
Mutant mice
APPSwe (Tg2576) mice, expressing mutant human APP
(K670N/M671L) under the control of the hamster prion
promoter (Hsiao et al., 1996) were obtained from Taconic
farms. Mice were maintained by breeding Tg2576 males in
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C57BL/6  SJL F1 genetic background with C57BL/6  SJL
F1 wild-type females, as recommended by the supplier. Mice
were genotyped by polymerase chain reaction (PCR) using
primer set 50-CGACTCGACCAGGTTCTGGGT-30, 50-
ATAACCCCTCCCCCAGCCTAGA-30. The ampliﬁcation con-
ditions were as follows. PCR reaction mixture: 1 buffer,
2mM MgCl2, 0.2mM dNTP, 0.75 mM APP forward primer,
0.75 mM APP reverse primer, 0.025mM Taq polymerase
(Invitrogen), 2ml/reaction. PCR program: (i) initialization:
94C for 3min; (ii) 35 cycles – denaturation: 94C for 30 s,
annealing: 60C for 60 s, extension: 72C for 60 s; (iii) ﬁnal
hold: 4C. Cortico-hippocampal tissue from 4 month: (n = 3)
and 12-month-old (n = 4) Tg2576 mutants as well as wild-type
littermates (4 months, n = 4; 12 months, n = 4) were used for
analysis by immunoblotting. Sexes of the animals were
balanced.
Cyﬁp2tm1a(EUCOMM)Wtsi/Wtsi mice (EM:05949) were gener-
ated in a C57BL/6N background by European Conditional
Mouse Mutagenesis Program (EUCOMM). These mutants
have an insertion of a promoter-driven neo gene in an intron
of the Cyﬁp2 gene, which results in a null mutation (Kumar
et al., 2013). Therefore, we designated these heterozygous mu-
tants as Cyﬁp2+ / mice. Cyﬁp2+ / mice were maintained in
the C57BL/6N background. Mice were genotyped by PCR.
The mutants were detected by mutant allele speciﬁc 248 bp
PCR product (forward CYFIP2 primer 50-TTCCTTCCT
TCCCTTGTCCC-3’, reverse CASR1 primer 50-TCGTGGTA
TCGTTATGCGCC-3’) and wild-type mice had only the
wild-type allele speciﬁc 461 bp PCR product (forward
CYFIP2 primer 50-TTCCTTCCTTCCCTTGTCCC-3’; reverse,
CYFIP2 primer 50-TGCCAGGAGAGACAGTGGTG-3’). The
PCR reaction consisted of 1 buffer, 1mM MgCl2, 0.2mM
dNTP, 10 mM primers and 0.125ml Taq DNA polymerase (5
U/ml; Invitrogen). The PCR protocol consisted of a 2min heat-
ing at 93C, followed by 35 cycles of denaturation (30 s,
93C), annealing (30 s, 56C) and extension (30 s, 72C). At
the end of the PCR cycle, samples were heated for 10min at
72C and held at 4C until recovered.
Mice were housed on 12 h light:12 h dark cycles with food
and water available ad libitum. All animal procedures were
conducted in accordance with the UK Animals Scientiﬁc
Procedures Act 1986.
Protein preparation from mouse brain
Frozen tissue from Tg2576 mice was homogenized at 100mg
tissue/ml 2 sample buffer (0.5M Tris-HCl, pH 6.8, 4.4%
SDS, 20% glycerol, 2% 2-mercaptoethanol, 0.01% bromophe-
nol blue, and complete mini-protease inhibitor cocktail)
(Roche), using a mechanical homogenizer. Following brief son-
ication, homogenates were centrifuged at 25 000g for 20min
at 4C, and the supernatant was collected.
For preparation of crude synaptosomes from Cyﬁp2+ / mu-
tants and wild-type littermates, frozen hippocampi were homo-
genized (10 strokes, 750 rpm) in 20 ml/mg homogenization
buffer (0.32M sucrose, 1mM NaHCO3, 1mM MgCl2,
10mM HEPES pH 7.4). A small volume was collected for
analysis of total hippocampal lysates. Following centrifugation
at 381g for 10min, 4C to remove nuclei and cell debris, the
resulting supernatant was centrifuged at 16 089g for 15min to
obtain a crude synaptosomal pellet. Synaptosomal pellets (P2
fraction) were resuspended in 300 ml homogenization buffer for
each 50mg of starting tissue.
A BCA-based protein quantiﬁcation procedure (Thermo
Fisher) was used to determine protein amounts for all mouse
samples.
Primary neuronal cell culture
Cortical tissues were prepared from embryonic Day 16 mice as
described (Pooler et al., 2012). The cells were plated on 6-well
dishes coated with poly-D-lysine in neurobasal media (without
L-glutamine; with phenol red) containing 2% B27 supplement
(Invitrogen), 0.5mM L-glutamine, and penicillin/streptomycin
(50 U/ml / 50 mg/ml, Sigma). After 4 days the cells were cul-
tured in selection media (to remove non-neuronal cells): neu-
robasal media (without L-glutamine; with phenol red)
containing 2% B27 supplement (Invitrogen), 0.5mM L-gluta-
mine, penicillin/streptomycin, and 3 mM cytosine, b-D-arabino-
furanoside. Cells were harvested as described below 21 days
after plating.
Glial cell culture
Glial cells were isolated from postnatal Day 1–4 (P1–P4)
mouse cerebral cortices, as previously described (Williams
and Price, 1995) and cultured on poly-D-lysine (25 mg/ml,
Sigma) coated T75 ﬂasks at a density of two to three cortices
per ﬂask in Dulbecco’s modiﬁed Eagle medium (Gibco), sup-
plemented with 10% foetal bovine serum (Biosera) and peni-
cillin/streptomycin (50 U/ml/50 mg/ml, Sigma). Once these
cultures reached conﬂuence (12–14 days) they were composed
of a base layer of non-dividing astrocytes and an upper layer
of dividing microglia and a few oligodendrocytes. For western
blot analysis these cells were plated onto 6-well plates; they
were harvested from each well using a sterilized scraper and in
the presence of 20 ml 2 sample buffer: 0.5M Tris-HCl, pH
6.8, 4.4% SDS, 20% glycerol, 2% 2-mercaptoethanol, 0.01%
bromophenol blue, and 10% mini-protease inhibitor cocktail
(Roche).
Western blot analysis
Protein samples were diluted and boiled at 95C in Laemmli
sample buffer. Comparable protein amounts were separated on
4–15% CriterionTM TGXTM precast gels (Bio-Rad) and then
transferred onto a methanol-activated 0.2mm polyvinylidene
ﬂuoride membrane (Bio-Rad). Membranes were blocked at
room temperature for 1h (5% milk in TBST pH 7.5) and then
incubated in primary antibody diluted in blocking buffer over-
night at 4C. Primary antibodies were detected using horseradish
peroxidase (HRP)-conjugated secondary antibodies (Dako,
P0447/8) and chemiluminescent reagent (Thermo Scientiﬁc), and
signals in the linear range obtained by exposing membranes to X-
ray ﬁlms (Amersham). Prior to probing with other primary anti-
bodies, the membranes were washed in western blot stripping
buffer (Santa Cruz Biotechnology). Primary antibodies used
were against amyloid-b sequence in APP (Millipore, MABN10,
1:300), APP-CTF sequence in APP (1:10000; a gift from Prof.
C.C. Miller, King’s College London), BACE1 (Gene Tex,
GTX62419, 1:5000), aCaMKII (Chemicon, MAB8699,
1:100000), CYFIP1 (Millipore, 07-531, 1:1000), CYFIP2
(GeneTex, GTX124387, 1:1000), Lamin B1 (Abcam,
ab133741, 1:5000), NSE (Millipore, AB951, 1:60000), synapto-
physin (Cell Signaling, 4329, 1:1000), a-synaptotagmin (Sigma,
S2177, 1:30000), phosphoSer214-tau (Abcam, AB10891, 1:250),
total tau (Dako, A0024, 1:10000) and b-tubulin III (Sigma,
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T8578, 1:1000). Signals were analysed with ImageJ software
(NIH).
Amyloid-b42 ELISA
Frozen hippocampal tissue was weighed and manually homo-
genized in 8 mass of cold 5M guanidine hydrochloride/
50mM Tris HCl pH 8.0 using a small piston homogenizer.
Homogenates were shaken at room temperature for 4 h and 5-
fold diluted in cold BSAT-DPBS (5% bovine serum albumin,
0.03% Tween-20, 2.7mM KCl, 1.5mM KH2PO4, 136.9mM
NaCl, 8.1mM Na2HPO4) supplemented with protease inhibi-
tor cocktail (Sigma). Diluted samples were centrifuged at
27 287g for 30min and the supernatants (containing GuHCl-
soluble amyloid) were collected and stored on ice until use.
Supernatants were further 10-fold diluted in standard diluent
buffer (supplied) and the assay was carried out according to
manufacturer’s instructions (Life Technologies, KMB3441).
Samples were measured in duplicates and the entire assay per-
formed twice. As a positive control, tissue from 12-month-old
Tg2576 mice was prepared in the same way.
RNA isolation and quantitative PCR
analysis
Total RNA was extracted from hippocampal tissue using
TRIzol (Life Technologies) and puriﬁed using RNeasy spin
columns (Qiagen). RNA (1.5 mg) from each sample was reverse
transcribed using SuperScriptTM II reverse transcriptase
(Invitrogen). The cDNA obtained was diluted 10 and
stored at 20C until use. Quantitative RT-PCR experiments
were performed using a Chromo4TM Continuous Fluorescence
Detector (Bio-Rad DNA Engine) with KAPA SYBR FAST
Master Mix as a reference dye (KAPA Biosystems). Speciﬁc
exon primers were designed across introns to unambiguously
distinguish spliced cDNA from genomic DNA contamination
and purchased from Integrated DNA Technologies. Primers
used were APPForward 5
0-ACTCTGTGCCAGCCAATACC-3’;
APPReverse 5
0-GAACCTGGTCGAGTGGTCAG-3’; BACE1
Forward 5
0-GACCACTCGCTATACACGGG-3’; BACE1Reverse
50-TCCTTGCAGTCCATCTTGAGA-3’; CaMKIIForward 50-TC
AGCATCCCAGCCCTAGTT-3’; CaMKIIReverse 5
0-AAGGCTC
CCTTTCCCAGTTC-3’; HPRT-LForward 5
0-GCTGGTGAAAA
GGACCTCT-3’; HPRT-LReverse 5
0-CACAGGACTAGAACAC
CTGC-3’. Optimum primer and cDNA concentrations were
empirically determined; each primer was used at a ﬁnal con-
centration of 300 nM and all cDNA was further diluted 50 .
The reaction was performed in Thermo-Fast white 96-well
plates capped with Ultra Clear caps (both Thermo Fisher).
The reaction mixture was heated at 95C for 10min followed
by 45 cycles (30 s at 95C, 30 s at 60C, 30 s at 72C), and
PCR product levels measured using Opticon Monitor version
3.1.32 (Bio-Rad). Samples were tested in duplicates or tripli-
cates and the entire assay performed twice. mRNA levels were
normalized to that of the housekeeping gene Hprt1, and the
Livak method (or Ct) was used for analysis.
Golgi-Cox staining
Female litters aged 15 weeks of either Cyﬁp2 + / (n = 4) or
wild-type genotypes (n = 5) were used to analyse spine density
using modiﬁed Golgi-Cox staining method as described by the
manufacturer (Rapid Golgi; FD NeuroTechnologies). Brieﬂy,
brains were removed from skull as quickly as possible,
rinsed in Milli-Q water and stored in Golgi impregnation
solution at room temperature in the dark for 2 weeks.
Tissue was then transferred into Golgi solution C for 1 week
in the dark at room temperature. Coronal sections (150 mm)
were obtained using a cryostat and mounted on 2% gelatine-
coated glass slides. Sections were rinsed, stained with solution
C, dehydrated, cleared of xylene, and were cover slipped and
allowed to dry before quantitative analysis. Several pyramidal
neurons impregnated with the Golgi solution were readily
identiﬁed in the dorsal hippocampal region by their character-
istic triangular soma shape and numerous dendritic spines. For
spine quantiﬁcation, a 100 oil-immersion objective was used
to identify spines in distal dendrites (150 mm away from soma)
longer than 10 mm. Straight branches were preferred for Z-
stack reconstructions to have a clear presentation of spines.
More than 50 dendritic segments were analysed for both
groups in apical and basal dendrites. Spine densities were cal-
culated as mean numbers of spines per micrometre per den-
drite in individual mice per group using ImageJ (NIH). Spines
were classiﬁed as long-thin, ﬁlopodia, or stubby/mushroom, as
described (Harris and Stevens, 1989; Harris et al., 1992).
Morris water maze studies
The study with the Cyﬁp2 + / mice and control littermates was
performed blind to genotype. Three to 4.5-month-old mutants
(10 males) and wild-type mice (13 males) were tested in the
hidden-platform version of the water maze. The diameter of
the swimming pool was 1.5m, the platform diameter 0.1m.
After handling the mice for 10 days, 2min/day, the mice were
tested with four trials per day for 10 days. The maximal trial
length was 90 s and the intertrial interval was 60 s. Probe trials
(60 s) were given at the end of training Day 10 and 5 days
after the ﬁrst probe trial. Four wild-type and three mutants
were excluded from analysis due to ﬂoating during probe
tests. Another group of mice (Cyﬁp2 + /: eight males, wild-
type: eight males) were tested with a visible platform using
two trials with a 60 s intertrial interval after hidden platform
training for 6 days. Video-tracking and EthoVision XT
(Noldus) were used to analyse swimming speed and search
strategies.
Social behaviour and marble burying
behaviour
Social behaviour
The three-chamber social approach task was performed based
on a published method (Yang et al., 2011). Brieﬂy, the subject
mouse was habituated to the centre chamber for 10min and
then all three chambers for 10min. Sociability was tested for
10min by assessing whether the subject mouse spent more
time in the chamber containing a novel mouse (129S2/Sv
strain) or in the chamber with an empty cup as novel object.
Social novelty was tested for 10min by assessing whether the
subject mouse prefers the chamber containing the ﬁrst novel
mouse or a second novel mouse placed inside the previously
empty object cup. Time spent in each chamber was measured
using EthoVision XT tracking system (Noldus).
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Marble burying
The experiments were performed based on a published method
(Deacon, 2006). Mice were individually placed for 30min in
animal cages (30 cm  16 cm) containing 5 cm deep bedding
and 18 marbles arranged in three evenly spaced rows of six
marbles each. The number of marbles that remained unburied
in each 10min interval was counted. Marbles were counted as
buried if they were at least covered two-thirds with bedding.
Statistical analysis
Unless otherwise speciﬁed, data were analysed with t-tests.
Post-mortem human brain studies
Statistical analysis for individual datasets was performed using
unpaired t-tests. The pooling of data from two sets of post-
mortem tissue samples that were separately obtained was per-
formed using a linear regression model based on the following
equation (see also, Tiwari et al., 2015):
ðCYFIP2=NSEÞi ¼ b0 þ b1X1i þ b2X2i þ "i ð1Þ
Where V1i is the categorical predictor coding for the group
difference (e.g. Control versus Severe), and V2i is the categor-
ical predictor coding for the different experiments (‘1st cohort’
versus ‘2nd cohort’)
This regression model allowed us to pool the CYFIP2 data
from the two different sets of post-mortem tissues thereby
eliminating potential variability resulting from differences in
experimental conditions. Data analysis was performed using
SPSS (version 20), which provides the output as a P score
indicating the overall signiﬁcance. The contribution and the
signiﬁcance of speciﬁc factors of interest, e.g. the disease path-
ology, are subsequently provided by t-test analysis. Hence, this
analysis strategy helps to identify the signiﬁcant change of
altered CYFIP2 scores in diseased brain samples when com-
pared to control tissues eliminating any effect induced by the
processing of different sample sets. The level of signiﬁcance for
the analysis was 0.05 and the outliers were identiﬁed as being
out with a threshold of mean  4  standard deviation (SD).
Behavioural studies
One-way ANOVA, one-way ANOVA on ranks (if data were
not distributed normally), two-way ANOVA with repeated
measures, and Student-Newman-Keuls tests were used for stat-
istical analysis as appropriate.
Results
Reduced CYFIP2 expression in post-
mortem Alzheimer’s disease
forebrain
To assess whether regulation of local mRNA translation
might be affected in Alzheimer’s disease, we investigated
CYFIP2 protein levels in forebrain samples of severe disease
cases and controls, all of which had short post-mortem delay
(Supplementary Table 1 and Supplementary
material). Antibodies that react speciﬁcally with CYFIP2
and neuron-speciﬁc enolase (NSE) protein, a neuronal
marker (McAleese et al., 1988), were used in western blots
(Supplementary Fig. 1). Considering that CYFIP2 is not ex-
pressed in glial cells (Supplementary Fig. 2), CYFIP2 expres-
sion normalized to NSE expression estimates CYFIP2
expression per neuron at the time of death. We found that
CYFIP2 expression was signiﬁcantly reduced by 40% in
hippocampus of late Alzheimer’s disease (Braak stages V–VI)
in comparison to expression in control subjects (t = 2.33;
P5 0.05; see Supplementary material) (Fig. 1A and B).
CYFIP2 protein is expressed at synapses (Pathania et al.,
2014). Therefore, reduced CYFIP2 expression in severe
Alzheimer’s disease might be due to synapse loss that occurs
before neuronal loss (Arendt, 2009). Alternatively, reduced
CYFIP2 expression may occur before synapses die in
Alzheimer’s disease. We tested for this possibility by normal-
izing CYFIP2 expression to the presynaptic marker synapto-
physin (Sudhof et al., 1987). We found that CYFIP2/
synaptophysin expression was signiﬁcantly decreased by
40% in severe Alzheimer’s disease hippocampus (t = 2.43;
P50.05; Supplementary Fig. 3), suggesting that CYFIP2 ex-
pression declines before synapse loss occurs.
We also studied CYFIP2 expression in the STG, which is
affected to a lesser extent and at later stages than the
hippocampus in Alzheimer’s disease (Braak and Braak,
1991). CYFIP2 expression was found to be signiﬁcantly
downregulated in severe Alzheimer’s disease STG
(t = 3.28, P50.01; Fig. 1C), supporting our ﬁnding of
reduced CYFIP2 expression in the hippocampus.
To investigate if these dysregulations are already present
in the early stages of the disease, we analysed hippocampal
lysates from patients with mild Alzheimer’s disease (Braak
stages I–II). There was a statistical trend towards a reduc-
tion of CYFIP2 expression by 50% in these cases
(t = 2.02, P = 0.056; Fig. 1D). These data suggested that
CYFIP2 downregulation may be an early event in
Alzheimer’s disease.
CYFIP2 binds to FMRP, a regulator of local mRNA
translation (Schenck et al., 2001). Therefore, we studied
whether not only CYFIP2 expression but also FMRP ex-
pression would be altered in severe Alzheimer’s disease
hippocampus (Supplementary Fig. 4). However, we did
not ﬁnd any evidence that FMRP levels are changed in
severe Alzheimer’s disease (t = 0.33, P = 0.75), suggesting
that the reduced CYFIP2 expression is speciﬁc.
Age-dependent reduction of CYFIP2
expression in an Alzheimer’s disease
mouse model
We investigated if the reduced CYFIP2 expression observed
in post-mortem Alzheimer’s disease brain (Fig. 1A–D) can
also be found in a mouse model of a familial form of the
disease. Tg2576 mice expressing APP with the Swedish mu-
tations do not have amyloid plaques and spatial memory
impairment at 4 months of age, whereas they have amyloid
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plaques and spatial memory deﬁcits at 12 months of age
(Hsiao et al., 1996; Stewart et al., 2011). We performed a
western blot analysis for CYFIP2 expression at these two
ages. The comparison revealed signiﬁcant differences be-
tween genotypes. CYFIP2 expression was signiﬁcantly
reduced by 50% in Tg2576 mice in comparison to wild-
type mice at 12 months of age (t = 6.56, P5 0.01; Fig. 1E
and G). The reduction in CYFIP2 expression is age-depend-
ent, as it was not found for 4-month-old mice (t = 1.03,
P = 0.34; Fig. 1F and H). Reduced CYFIP2 expression by
Figure 1 Reduced CYFIP2 expression in post-mortem Alzheimer’s disease forebrain and in a mouse model of familial
Alzheimer’s disease. (A–D) CYFIP2 expression is decreased in forebrain of patients with severe Alzheimer’s disease. (A) Representative
western blots. (B) CYFIP2 expression in hippocampal lysates from patients with severe Alzheimer’s disease (n = 9) and control subjects (n = 11).
(C) CYFIP2 expression in lysates of STG from patients with severe Alzheimer’s disease (n = 13) and control subjects (n = 12). (D) CYFIP2
expression in hippocampal lysates of patients with mild Alzheimer’s disease (n = 12) and control subjects (n = 12). (E–G) Age-dependent decrease
of CYFIP2 expression in forebrain of Tg2576 mice. (E and F) Representative western blots. (G) CYFIP2 expression in hippocampal–cortical
lysates of 12-month-old wild-type mice (n = 4) and Tg2576 (n = 3). (H) CYFIP2 expression in hippocampal-cortical lysates of 4-month-old wild-
type (n = 4) and Tg2576 mice (n = 4). In all panels CYFIP2 expression was normalized against NSE. Means  standard error of the mean (SEM) are
shown. *P5 0.05; **P5 0.01.
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50% in 12-month-old Tg2576 mice resembles the
reduced CYFIP2 expression in post-mortem Alzheimer’s
disease forebrain. Further, it suggests that abnormal APP
processing may be sufﬁcient to cause CYFIP2
downregulation.
CYFIP1 expression is not changed in
mild Alzheimer’s disease hippocam-
pus and severe Alzheimer’s disease
STG
As CYFIP1 has similar functions in vitro to CYFIP2
(Abekhoukh and Bardoni, 2014), we wanted to know if
CYFIP1 could be implicated in mild stages of Alzheimer’s
disease. We performed western blot analysis with hippo-
campal protein from patients with mild Alzheimer’s dis-
ease and did not observe a downregulation of CYFIP1
expression (t = 1.28, P = 0.22; Supplementary Fig. 5A
and B), contrary to the results for CYFIP2 expression
(Fig. 1D). There was also no change of CYFIP1 expres-
sion in STG tissues from patients with severe Alzheimer’s
disease (t = 1.15, P = 0.26; Supplementary Fig. 5C), as
opposed to CYFIP2 reduction seen in severe Alzheimer’s
disease STG (Fig. 1C). There appeared to be an upregu-
lation in CYFIP1 levels in severe Alzheimer’s disease
hippocampus (t = 3.27, P50.01; Supplementary Fig.
5D), contrary to the signiﬁcant downregulation of
CYFIP2 expression (Fig. 1B). These results indicate that
CYFIP1 and CYFIP2 are regulated differently in
Alzheimer’s disease hippocampus.
We further studied whether CYFIP1 expression is altered
in old Tg2576 mice, which model early stages of
Alzheimer’s disease. As for CYFIP2 (Fig. 1E–H), we per-
formed western bot analysis for CYFIP1 expression using
the same forebrain tissues of Tg2576 mice and controls. In
4-month-old Tg2576 mouse forebrain there was no change
in CYFIP1 expression as compared to wild-type mice
(t = 0.97, P = 0.37; Supplementary Fig. 5H). Unexpectedly,
we found a downregulation of CYFIP1 expression by
60% in 12-month-old Tg2576 mice (t = 5.49,
P50.01; Supplementary Fig. 5G), instead of an upregula-
tion of CYFIP1 expression observed in post-mortem, severe
Alzheimer’s disease hippocampus (Supplementary Fig. 5D).
CYFIP2 regulation is independent of
CYFIP1 regulation
We studied the functional impact of reduced CYFIP2 ex-
pression in Cyﬁp2 + / mice. We conﬁrmed earlier work
(Kumar et al., 2013) that showed that these mutants have
reduced CYFIP2 protein expression by 50% in hippocam-
pal synaptosomes in comparison to wild-type littermates
(t = 4.90, P5 0.001; Fig. 2A and B) (for speciﬁcity of hip-
pocampal synaptosomes, see Supplementary Fig. 6), and
40% in total hippocampal lysates (Supplementary Fig.
7A and B). Further, we found that CYFIP1 expression
was not altered in hippocampal synaptosomes from
CYFIP2 + / mutants in comparison to wild-type littermates
(t = 0.13, P4 0.090; Fig. 2A and B). Hence, we showed
that CYFIP1 and CYFIP2 expression regulations are not
dependent on each other.
Reduced CYFIP2 leads to upregula-
tion of APP protein, but not mRNA
expression
At synapses APP mRNA is locally translated in an FMRP-
dependent manner (Westmark, 2013). As CYFIP2 interacts
with FMRP (Schenck et al., 2001), we tested whether
reduced CYFIP2 expression impacts on APP protein expres-
sion. Western blot analysis with an antibody directed
against the C-terminus of APP showed that full-length
APP protein expression was signiﬁcantly elevated 2-fold
in hippocampal synaptosomes of Cyﬁp2 + / mice in com-
parison to wild-type littermates (t = 4.84, P5 0.001; Fig.
2C and D). About a 2-fold upregulation of full-length
APP protein expression in hippocampal synaptosomes
from Cyﬁp2 + / mice was conﬁrmed with an antibody
reacting against an epitope in amyloid-b sequence (data
not shown). We did not detect a signiﬁcant increase of
full-length APP expression in total hippocampal lysates
(Supplementary Fig. 7A and B), suggesting that the increase
occurs primarily at synapses. We studied whether or not
the increased APP expression in Cyﬁp2 + / mice could be
due to increased App mRNA expression. Quantitative RT-
PCR (qPCR) analysis showed that the levels of App mRNA
in hippocampus did not differ between Cyﬁp2 + / mutants
and wild-type littermates (t = 0.007, P40.99; Fig. 2E).
This result shows that reduced CYFIP2 expression impacts
post-transcriptionally on APP expression.
Reduced CYFIP2 leads to upregula-
tion of BACE1 protein, but not
mRNA, and abnormal production of
amyloid-b42
Translation of the mRNA encoding b-site APP cleaving
enzyme 1 (BACE1) is increased by amyloid-b42 action on
cultured neurons (Sadleir et al., 2014; Mamada et al.,
2015) and in an Alzheimer’s disease mouse model
(Caccamo et al., 2015). As the elevated APP protein, but
not mRNA, expression in Cyﬁp2+ / mutants (Fig. 2C–E)
suggested that reduced CYFIP2 expression leads to
increased translation of particular mRNAs, we tested
whether BACE1 expression was altered. Western blot ana-
lysis showed that BACE1 protein expression was signiﬁ-
cantly elevated in hippocampal synaptosomes by 40%
in Cyﬁp2+ / mice in comparison to wild-type littermates
(t = 2.36, P5 0.05; Fig. 3A and B). This change was not
observed in total hippocampal lysates (Supplementary Fig.
7A and B), possibly due to high levels of BACE1 expression
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in non-synaptic fractions (data not shown), suggesting
BACE1 expression is mainly elevated at synapses in
Cyﬁp2 + / mutants. Quantitative PCR analysis showed
that the Bace1 mRNA expression level was not altered in
the hippocampus of Cyﬁp2 + / mutants (t = 0.48, P = 0.64;
Fig. 3C). Thus, reduced CYFIP2 expression impacts on the
post-transcriptional expression of BACE1. In previous stu-
dies higher levels of BACE1 protein expression have been
associated with abnormal APP cleavage and higher amyl-
oid-b42 production (Caccamo et al., 2015). Therefore, we
studied whether amyloid-b42 production is elevated in
hippocampus of Cyﬁp2 + / mutants. As expected, an
ELISA showed that amyloid-b42 production was increased
by 30% in hippocampus of Cyﬁp2 + / mutants in com-
parison to wild-type littermates (t = 3.18, P5 0.01; Fig.
3D). These ﬁndings indicate that reduced CYFIP2 expres-
sion affects APP processing.
Reduced CYFIP2 leads to upregula-
tion of aCaMKII protein, but not
mRNA, and increases tau
phosphorylation
Like App mRNA, Camk2a (aCaMKII) mRNA is locally
translated in an FMRP-dependent manner (Napoli et al.,
2008). Moreover, recent studies have suggested that
increased aCaMKII activity contributes to tau hyperpho-
sphorylation in Alzheimer’s disease (Ghosh and Giese,
2015). Therefore, we studied whether reduced CYFIP2 ex-
pression affects aCaMKII expression in the hippocampus.
Western blot analysis showed that aCaMKII protein
expression was signiﬁcantly elevated 2.5-fold in hippo-
campal synaptosomes in Cyﬁp2 + / mice in comparison to
wild-type littermates (t = 3.05, P5 0.05; Fig. 4A and B).
This effect was not observed in total hippocampal lysates
(Supplementary Fig. 7A and B). This is likely due to a di-
lution of synaptic signal in total lysates as aCaMKII is also
highly expressed in somata and dendrites of hippocampal
neurons (Giese et al., 1998). Quantitative PCR analysis
showed that the Camk2a/aCaMKII mRNA expression
level was not altered in the hippocampus of Cyﬁp2 + / mu-
tants (t = 0.39, P = 70; Fig. 4C). This result suggests that
CYFIP2 regulates translation of Camk2a/aCaMKII mRNA.
We tested also whether the increased aCaMKII protein ex-
pression correlates with altered tau phosphorylation at
serine-214 (S214), a site that is phosphorylated by
CaMKII, and one of the key sites that are hyperphosphory-
lated in Alzheimer’s disease (Lee et al., 2001). The expres-
sion of total tau was not altered in Cyﬁp2+ / mutants in
comparison to wild-type littermates (t = 0.31, P = 076; Fig.
4D and F). However, phosphorylation of tau at S214 was
signiﬁcantly increased by 60% in Cyﬁp2 + / mice in com-
parison to wild-type littermates (t = 3.63, P5 0.01; Fig. 4D
and E).
Reduced CYFIP2 affects spine mor-
phology on apical, but not basal,
dendrites of hippocampal CA1
pyramidal neurons
CYFIP2 not only binds to FMRP, it is also part of the
WAVE complex (Eden et al., 2002), which regulates actin
polymerization. As CYFIP1 is also part of the WAVE com-
plex and because reduced CYFIP1 expression affects den-
dritic spine morphology of hippocampal CA1 pyramidal
neurons (De Rubeis et al., 2013; Pathania et al., 2014),
we studied whether reduced CYFIP2 expression would
also alter dendritic spines. Using Golgi-Cox staining, we
analysed dendritic spines on apical and basal segments of
CA1 pyramidal neurons of Cyﬁp2 + / mutants and wild-
type littermates (Supplementary Fig. 8). There was no sig-
niﬁcant difference in spine density between the genotypes
for apical distal segments (t = 0.095, P = 0.93) or for basal
distal segments (t = 0.10, P = 0.92) (Supplementary Fig. 8C
and D). Next, we categorized the spines into three classes:
long-thin, ﬁlopodia and stubby-mushroom spines according
to widely used criteria (Harris and Stevens, 1989; Harris
et al., 1992) (Fig. 5A). Comparison of these spine types on
apical distal dendrites revealed a signiﬁcant difference be-
tween genotypes (Fig. 5B). Compared to wild-type litter-
mates, Cyﬁp2 + / mutants had a greater proportion of
long-thin spines (55% for mutants versus 39% for wild-
types; t = 3.45, P5 0.05) and a smaller proportion of
stubby/mushroom spines (36% for mutants versus 51%
for wild-types; t = 3.51, P5 0.01). The proportion of ﬁlo-
podia, however, remained constant between the two groups
(t = 0.61, P = 0.56). In contrast with the differences in
apical spine morphology between genotypes, we found
that the abundance of spine types on basal dendrites was
not altered in Cyﬁp2 + / mutants (long-thin, t = 0.34,
P = 0.75; ﬁlopodia, t = 0.99, P = 0.37; stubby/mushroom,
t = 0.51, P = 0.63; Fig. 5C). These ﬁndings show that
reduced CYFIP2 expression affects spine morphology only
in particular dendritic segments of CA1 pyramidal neurons.
Reduced CYFIP2 impairs retention of
spatial memory
Hippocampus-dependent spatial memory is affected in the
early stages of Alzheimer’s disease. To investigate whether
reduced CYFIP2 expression affects spatial memory forma-
tion, we studied the Cyﬁp2+ / mutants and wild-type litter-
mates in the hidden platform version of the water maze
(Fig. 6). The mice were trained with four trials per day for
10 days. The genotypes did not differ in latency to locate the
platform [two-way ANOVA with repeated measures; effect
of genotype F(1,14) = 0.29, P = 0.60; effect of training
F(9,126) = 18.9, P5 0.001; genotype  training interaction
F(9,126) = 0.91, P = 0.52] (Fig. 6B). Studies with a separate
cohort of mice indicated that Cyﬁp2+ / mutants had normal
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visible platform learning (time to reach platform for wild-
type mice, 9.6  1.5 s; for mutants, 11.1  2.7 s; one-way
ANOVA on ranks H = 0.025, P = 0.88. This indicates that
the Cyﬁp2+ / mutants were not impaired in swimming abil-
ities, motivation, and vision. To assess hippocampus-depend-
ent spatial memory, probe trials were performed. A probe
trial given at the end of training Day 10 (P1) showed that
Cyﬁp2+ / mutants formed normal spatial memory after
training (Fig. 6C). However, a second probe trial given 5
days after ﬁrst probe test (P2) revealed that Cyﬁp2+ / mu-
tants were impaired in retention of spatial memory, in con-
trast with wild-type littermates (Fig. 6C). During these probe
trials the average swimming speed did not signiﬁcantly differ
between genotypes [P1: wild-type mice, 21.7  2.0 cm/s; mu-
tants, 24.3  2.7 cm/s; one-way ANOVA with genotype as
variable, F(1,14) = 4.58, P = 0.051; P2: wild-type,
22.1  1.60 cm/s; mutants, 24.1  2.3 cm/s; one-way
ANOVA with genotype as variable, F(1,14) = 3.90,
P = 0.068]. Analysis of search time in the four quadrants
during probe trial P1 showed that Cyﬁp2+ / mutants and
wild-type littermates searched selectively [one-way ANOVA
with analysis of the quadrant as variable; mutants,
F(3,24) = 9.65, P5 0.001; wild-type mice, F(3,32) = 17.3,
P5 0.001] (Fig. 6C). The mutants and wild-type mice
spent more time searching in the target quadrant than in
any other quadrant (Student-Newman-Keuls test; mutants,
P5 0.001 target quadrant versus opposite quadrant and ad-
jacent left quadrant, P = 0.002 target quadrant versus adja-
cent right quadrant; wild-type, P5 0.001 target quadrant
versus opposite quadrant, adjacent left quadrant, adjacent
right quadrant). On the other hand, during probe trial P2
the Cyﬁp2+ / mutants searched randomly, spending similar
times in all quadrants [one-way ANOVA with quadrant as
variable, F(3,24) = 2.55, P = 0.08], in contrast with wild-type
littermates [one-way ANOVA with quadrant as variable,
F(3,32) = 8.47, P5 0.001]. The wild-type mice spent
more time searching in the target quadrant than in any
other quadrant (Student-Newman-Keuls test; P5 0.001
target quadrant versus opposite quadrant, P = 0.002 target
quadrant versus adjacent right quadrant, P = 0.004 target
quadrant versus adjacent left quadrant). Taken together,
these results indicate that Cyﬁp2+ / mutants are able to
form spatial memories, but they cannot maintain these
memories.
Figure 2 Reduced CYFIP2 expression does not affect CYFIP1 expression, but leads to increased APPexpression at protein but
not mRNA level in the hippocampus. (A) Representative western blots. (B) Quantification showed that CYFIP2 expression is reduced by
50% in hippocampal synaptosomes of Cyfip2+ / mice (black bar; n = 7) in comparison to wild-type littermates (grey bar, n = 8). CYFIP1 levels
are not significantly changed in the same lysates. For quantification CYFIP1 and CYFIP2 expression were normalized to levels of NSE, a neuronal
marker. (C) Representative western blots. (D) Quantification showed that APP protein expression is significantly increased 2-fold in hippo-
campal synaptosomes of Cyfip2+ / mice (black bar) in comparison to wild-type littermates (grey bar; n = 8 per genotype). (E) Quantitative PCR
analysis showed that App mRNA levels are not elevated in hippocampi of Cyfip2+ / mice (black bar) in comparison to wild-type littermates (grey
bar) when normalized to the housekeeping gene Hprt (n = 8 per genotype). Means  SEM are shown. ***P5 0.001.
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CYFIP2 downregulation does not
cause abnormal social and repetitive
behaviour
In humans heterozygous microdeletion of chromosome 15,
which includes the CYFIP1 gene, causes neurobehavioural
disturbances including autism (Abekhoukh and Bardoni,
2014; Cox and Butler, 2015). However, human genetic stu-
dies have not found a link between mutations of the CYFIP2
gene and autism. Further, CYFIP2 is expressed much later
during cortical development in comparison with CYFIP1
(Bonaccorso et al., 2015). We studied whether reduced
CYFIP2 expression in Cyﬁp2+ / mice affects social behaviour
in the three-chamber task and repetitive behaviour in the
marble burrowing task (Supplementary Fig. 9), two behav-
iours that are impaired in mouse models of autism
(Silverman et al., 2010; Santini et al., 2013). We found that
Cyﬁp2+ / mice did not signiﬁcantly differ from wild-type
littermates in these tasks. Thus, reduced CYFIP2 expression
might not cause any neurodevelopmental abnormalities that
lead to autism-like behaviours.
Discussion
Here, we show that expression of CYFIP2 protein is sub-
stantially reduced in Alzheimer’s disease forebrain and our
functional studies in mice suggest that this CYFIP2
downregulation links together amyloid production, tau
hyperphosphorylation and spatial memory loss.
Our previous studies on p25 dysregulation suggested that
CYFIP2 expression could be reduced in Alzheimer’s disease
(Engmann et al., 2011). Here, post-mortem expression ana-
lysis shows that this is the case. To assure that CYFIP2
expression is not simply reduced due to neuronal and syn-
aptic loss in Alzheimer’s disease, we normalized CYFIP2
levels to expression of a neuronal housekeeping protein
as well as to a synaptic vesicle protein. The decreased,
normalized CYFIP2 expression in post-mortem
Alzheimer’s disease forebrain indicates that CYFIP2 levels
decline before neurons and synapses die. We suggest that
CYFIP2 expression decreases already in the early stages of
Alzheimer’s disease, as we found an 2-fold reduction in
mild Alzheimer’s disease hippocampus (Braak stages I–II).
Consistent with this idea, we found that CYFIP2 protein
expression is reduced in an APP transgenic mouse line, the
Tg2576 mouse, which models early Alzheimer’s disease
(Hsiao et al., 1996; Stewart et al., 2011). This ﬁnding
also suggests that abnormal APP processing may be sufﬁ-
cient to decrease CYFIP2 expression. Follow-up investiga-
tions will be needed to characterize the mechanism by
which abnormal APP processing downregulates CYFIP2
expression.
We also investigated CYFIP1 protein expression in the
Alzheimer’s disease forebrain, as CYFIP1 and CYFIP2 are
thought to have similar functions in vitro, although these
Figure 3 Reduced CYFIP2 expression leads to increased BACE1 expression at protein, but not mRNA level, and abnormal
amyloid-b42 production in the hippocampus. (A) Representative western blots. (B) Quantification showed that BACE1 protein expression
is significantly upregulated by 40% in hippocampal synaptosomes of Cyfip2+ / mice (black bar) in comparison to wild-type littermates (grey bar;
n = 8 per genotype). (C) Quantitative PCR analysis showed that Bace1 mRNA levels are not elevated in hippocampus of Cyfip2+ / mice (black
bar) in comparison to wild-type littermates (grey bar; n = 8 per genotype). (D) An ELISA on whole hippocampi showed significantly elevated
amyloid-b42 levels by 30% in Cyfip2
+ / mutants (black bar; n = 4) versus wild-type littermates (grey bar; n = 5). Means  SEM are shown.
*P5 0.05, **P5 0.01.
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two proteins do not compensate for each other in the hap-
loinsufﬁcient state in mice or humans (De Rubeis et al.,
2013; Pathania et al., 2014; Cox and Butler, 2015). In
contrast to CYFIP2 expression, the level of CYFIP1 expres-
sion is not changed in post-mortem Alzheimer’s disease
brain, with the exception that CYFIP1 expression is ele-
vated in severe Alzheimer’s disease hippocampus. This par-
ticular increase in CYFIP1 expression in severe Alzheimer’s
disease hippocampus, but not in severe Alzheimer’s disease
superior temporal gyrus, may represent a late wave of fur-
ther neurodegeneration in the disease, or alternatively a
compensatory mechanism contributing to the survival of
some hippocampal neurons in the disease (West et al.,
1994). It is also important to note that a study of large
rare copy number variants in Alzheimer’s disease among
Caribbean Hispanics identiﬁed a nominal association be-
tween Alzheimer’s disease and a chromosomal duplication
that includes the CYFIP1 gene (Ghani et al., 2012). This
duplication was found in 10 Alzheimer’s disease cases
(2.6%) versus three controls (0.8%).
Synapse loss and the resulting impact on synaptophysin
expression is uneven within the Alzheimer’s disease hippo-
campus (Heinonen et al., 1995; Honer, 2003). Reduced
synaptophysin expression is pronounced in area CA1,
where most neuronal loss occurs (West et al., 1994).
Additionally, reduced synaptophysin expression is thought
to occur particularly in neurons with neuroﬁbrillary tangles
(Coleman et al., 2004; Arendt, 2009). However, in a west-
ern blot analysis where synaptophysin expression was nor-
malized to expression of a neuronal marker protein we and
others did not detect reduced synaptophysin expression in
Alzheimer’s disease hippocampal homogenates (Davidsson
et al., 1998; Tiwari et al., 2015). This is in agreement with
a recent study showing that in mammalian models of tauo-
pathy there is little evidence that synaptophysin expression
is lost when normalized to NSE expression in brain regions
Figure 4 Reduced CYFIP2 expression leads to increased aCaMKII expression at protein but not mRNA level, and increased
tau phosphorylation in the hippocampus. (A) Representative western blots. (B) Quantification showed that aCaMKII protein expression is
significantly upregulated 2-fold in hippocampal synaptosomes of Cyfip2+ / mice (black bar) in comparison to wild-type littermates (grey bar;
n = 8 per genotype). (C) Quantitative PCR analysis showed that Camk2a/aCaMKII mRNA levels are not elevated in hippocampus of Cyfip2+ /
mice (black bar) in comparison to wild-type littermates (grey bar; n = 8 per genotype). (D) Representative western blots. (E) Quantification
showed an 50% increase in phosphorylation of tau at serine-214 in hippocampal synaptosomes of Cyfip2+ / mice (black bar) in comparison to
wild-type littermates (grey bar; n = 8 per genotype). (F) Quantification showed that total levels of tau did not differ in hippocampal synaptosomes
of Cyfip2+ / mice (black bar) in comparison to wild-type littermates (grey bar; n = 8 per genotype). Means  SEM are shown. *P5 0.05,
**P5 0.01.
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affected by signiﬁcant neurodegeneration (Bondulich et al.,
2016). This suggests that synaptophysin levels are not
reduced in most neurons that have not yet died. A similar
observation was made for synapsin I expression in severe
Alzheimer’s disease cortex (Kurbatskaya et al., 2016),
whereas expression of other synaptic markers is altered
(Honer, 2003; Kurbatskaya et al., 2016).
We studied the functional impact of reduced CYFIP2 ex-
pression in heterozygous null mutant mice. We found that
reduced CYFIP2 expression increases APP and aCaMKII
expression in synapses at the post-transcriptional level,
similar to previous ﬁndings with CYFIP1 (Napoli et al.,
2008). FMRP binds to APP and CAMK2A/aCaMKII
mRNAs and suppresses their translation (Westmark and
Malter, 2007; Lee et al., 2010; Darnell et al., 2011).
Further, CYFIP2 binds to FMRP (Schenck et al., 2001)
and has a binding motif for the translational initiator
eIF4E (Napoli et al., 2008). Taken together, this suggests
that CYFIP2 normally suppresses translation of APP and
CAMK2A/aCaMKII mRNAs and that reduction of CYFIP2
expression is sufﬁcient to increase translation of these
mRNAs.
Studies with various models of Alzheimer’s disease have
suggested that there is a feed-forward mechanism of amyl-
oid-b42 production that involves elevated translation of
APP mRNA (Westmark et al., 2011; Westmark, 2013;
Sadleir et al., 2014; Caccamo et al., 2015). In this scenario,
increased APP protein expression would provide more ma-
terial for abnormal APP cleavage resulting in further amyl-
oid-b42 production. The amyloid-b42-induced elevation of
APP mRNA translation does not involve phosphorylation
of the translation initiation factor eIF2a (Sadleir et al.,
2014), and is not well understood at the mechanistic
level. Our work suggests that reduction of CYFIP2 expres-
sion is an important step in upregulating APP mRNA
translation in a feed-forward amyloid-b42 production pro-
cess. Additionally, recent studies have shown that amyloid-
b42 oligomers elevate BACE1 expression post-translation-
ally, suggesting that not only increased APP protein expres-
sion, but also enhanced BACE1 protein expression may be
part of a feed-forward mechanism for amyloid-b42 produc-
tion (Sadleir and Vassar, 2012; Mamada et al., 2015).
Interestingly, we found that reduced CYFIP2 expression
increases BACE1 expression at the post-transcriptional
level. As BACE1 mRNA is not regulated by FMRP
(Bufﬁngton et al., 2014), it is possible that this increased
expression is secondary to elevated amyloid-b42 production
resulting from increased APP protein expression when
CYFIP2 expression is reduced. Thus, reduction of
CYFIP2 expression may be an essential step for increasing
APP and BACE1 protein expression for the feed-forward
production of amyloid-b42.
A fundamental question in Alzheimer’s disease research is
how abnormal APP processing causes tau hyperphosphor-
ylation, which is a prerequisite for neuroﬁbrillary tangle
formation. Our work suggests that reduced CYFIP2 expres-
sion links amyloid production with tau hyperphosphoryla-
tion. Reduced CYFIP2 expression is suggested to increase
translation of mRNA encoding CAMK2A/aCaMKII, result-
ing in increased CaMKII activity, which leads to hyperpho-
sphorylation of tau (Sengupta et al., 1998; Wang et al.,
2007). Tau is phosphorylated at many different sites and
in this study we only investigated phosphorylation at S214,
a site that is hyperphosphorylated in Alzheimer’s disease
(Lee et al., 2001). Follow-up studies are needed to study
the impact of reduced CYFIP2 expression on tau phosphor-
ylation in much greater detail.
Our studies in mice have revealed that reduction of
CYFIP2 expression leads to a characteristic spatial
memory phenotype: spatial memory acquisition is not im-
paired but spatial memory cannot be retained and is lost
Figure 5 Reduced CYFIP2 expression leads to altered
spine morphology in apical dendrites of CA1 pyramidal
neurons. (A) Spines were classified as long-thin, filopodia, or
stubby/mushroom, according to criteria set by Harris et al. (1992).
Spines were imaged under bright-field microscopy using a 100 oil-
immersion objective. Scale bar = 0.5 mm. (B) Spines classified as a
proportion of total number of spines for apical dendritic segments
of dorsal CA1 pyramidal neurons. Wild-type (WT) controls (black
bars, n = 5) were compared to Cyfip2+ / mutants (grey bars, n = 4)
for long-thin spines (39% versus 55%), filopodia (6.7% versus 7.5%),
and stubby/mushroom (51% versus 36%). Cyfip2+ / mutants have
significantly more long thin spines, but less stubby-mushroom spines
than wild-type mice. (C) Spines classified as a proportion of total
number of spines for basal dendritic segments of dorsal CA1 pyr-
amidal neurons. Wild-type controls (black bars, n = 5) were com-
pared to Cyfip2+ / mutants (grey bars, n = 4) for long-thin,
filopodia, and stubby/mushroom spines. No difference was found
between the genotypes. Means  SEM are shown. *P5 0.05;
**P5 0.01.
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within a few days in comparison to normal wild-type mice.
To our knowledge there is only one other mutant mouse
with a similar spatial memory phenotype, mice lacking the
prion-like translational regulator CPEB3 (Fioriti et al.,
2015). Thus, it is conceivable that CYFIP2 and CPEB3
regulate the same mRNA translation, which is needed for
memory storage. Alternatively, reduced WAVE function
may account for the spatial memory loss in CYFIP2
mutant mice, as the mutants have more immature spines
and less mature (‘memory’) spines (Bailey et al., 2015). In
any case, it is intriguing that reduced CYFIP2 expression
links together spatial memory loss with amyloid production
and tau hyperphosphorylation, three features and hall-
marks of Alzheimer’s disease.
Recently, another laboratory has studied the phenotype
of a newly generated Cyﬁp2 heterozygous null mutant
mouse line (Han et al., 2015). These authors also showed
that reducing CYFIP2 expression does not impact on
CYFIP1 expression, but they suggested that CYFIP2 does
not regulate APP and aCaMKII protein expression. One
possible explanation for the discrepancy with our ﬁndings
is that Han et al. (2015) studied APP and aCaMKII expres-
sion in cortical, and not hippocampal, neurons. In cortical
neurons CYFIP2 expression is higher than in hippocampal
neurons (Han et al., 2015) and a higher level of residual
CYFIP2 expression may suppress a phenotype. However,
Han et al. (2015) found a dendritic spine phenotype in
cortical but not in hippocampal neurons in their CYFIP2
mutant mouse line. Therefore, it is conceivable that differ-
ences in genetic background account for the phenotypic
differences. Our Cyﬁp2 heterozygotes were maintained on
a C57BL/6N genetic background where the residual
CYFIP2 has a S968F point mutation that reduces the
half-life of CYFIP2 (Kumar et al., 2013), whereas Han
et al. (2015) used Cyﬁp2 heterozygotes in a C57BL/6J gen-
etic background. Applied to Alzheimer’s disease this could
suggest that genetic modiﬁers may suppress the impact of
reduced CYFIP2 expression on amyloid production, tau
hyperphosphorylation and spatial memory loss in some
patients.
In conclusion, to our knowledge this is the ﬁrst report mod-
elling a protein expression change detected in post-mortem
Alzheimer’s disease brain that causes a combination of amyl-
oid production, tau hyperphosphorylation and spatial
memory loss, i.e. key features of the disease. This suggests
that there are molecular ‘hubs’ that contribute to various as-
pects of Alzheimer’s disease, and that reduced CYFIP2 expres-
sion is one of these. Such ‘hubs’ could be ideal targets for
pharmacological treatment where a multitude of neurodegen-
erative processes may be rectiﬁed.
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